SciELO - Scientific Electronic Library Online

vol.19 número3Utilidad del campo magnético en la cervicobraquialgia crónicaUso del parche de capsaicina 8% para el tratamiento del dolor por infusión de treprostinil subcutáneo índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados



Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google


Revista de la Sociedad Española del Dolor

versión impresa ISSN 1134-8046


RODRIGO ROYO, M. D.; RIBERA CANUDAS, M. V.; LEDESMA MARTIN-PINTADO, F.  y  ZUBILLAGA MARBAN, E.. The clinical reason for prescribing OROS® hydromorphone in patients with chronic non-cancer: Study HIDOCO. Rev. Soc. Esp. Dolor [online]. 2012, vol.19, n.3, pp.125-133. ISSN 1134-8046.

Objective: to establish the clinical reasons for prescribing OROS® hydromorphone in patients with chronic non-cancer pain. Material and methods: an observational, retrospective, multicenter, Spanish study in patients with chronic non-cancer pain treated with OROS® hydromorphone between 1 and 5 months. The recorded information stemmed from the medical records of the patient, from the information given by the investigator of its clinical daily practice and from two questionnaires administered to the patient on adherence (Morisky-Green) and quality of life (SF-36). Results: 53 investigators included data of 438 patients with a mean age of 62 years, 43.4% of them under 60 years of age. The most prevalent pathological conditions were osteoarthritis and low-back pain. Despite the time from the onset of the pain was 6.4 years, 23.3% of the patients had been experiencing pain over 10 years. Before starting treatment with OROS® hydromorphone, 62% had VAS score >7 and 33.5% had VAS score 5-7. The combination of minor opioids and NSAIDs was the most common previous treatment, and only 5% were receiving strong opioids alone. The main reason for starting OROS® hydromorphone was the lack of efficacy with the previous opioid (62.1%), and the first criterion for the choice was efficacy (81.7%), followed by dosage (60.3%) and tolerability profile (47.7%). 93.4% of the patients stated that they regularly took their medicine at the right time and 57.8% considered that their current health condition was better or unchanged from the previous year. Conclusions: Undertreated pain and the lack of use of strong opioids in patients with chronic non-cancer pain are still important issues. OROS® Hydromorphone is a valid therapeutic option, with its efficacy, dosage and tolerability profile as the main reasons for its choice.

Palabras clave : Non-oncologic chronic pain; OROS® hydromorphone; Opioids; Adherence; Quality of life.

        · resumen en Español     · texto en Español     · Español ( pdf )


Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons